Nasdaq1mon
FDA approves Roche’s Evrysdi tablet as first and only tablet for Spinal Muscular Atrophy (SMA)
This approval marks another significant step forward," said Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development, Roche. "The Evrysdi tablet combines ...
Mena FN1mon
FDA Approves Roche’S Evrysdi Tablet As First And Only Tablet For Spinal Muscular Atrophy (SMA)
The 5 mg Evrysdi tablet ... Roche leads the clinical development of Evrysdi as part of a collaboration with the SMA Foundation and PTC Therapeutics. Evrysdi is a survival motor neuron 2 (SMN2 ...
Business Wire1mon
FDA Approves Genentech’s Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy (SMA)
--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX ... The new tablet, expected to be available in the coming weeks, is suitable for people 2 years of age or older who weigh more ...
Yahoo Finance1mon
FDA approves Roche’s Evrysdi tablet as first and only tablet for Spinal Muscular Atrophy (SMA)
Basel, 12 February 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for an Evrysdi® (risdiplam) ...